Bertram Capital has reached its $500 million target for its second growth equity fund, and is expecting to exceed that figure before holding a final close.
A person with knowledge of the fundraising told PEO Bertram Growth Capital II would likely close on over $500 million within the next few weeks, but had yet to pin down a final close amount. Approximately $20 million will come from a general partner commitment, the person said.
San Mateo, California-based firm Bertram focuses on buyouts and providing growth capital to mid-market companies in sectors such as healthcare, manufacturing, technology, and business services industries.
“We’re looking at several [companies] in the healthcare space and one in industrial manufacturing,” Jeff Drazan, managing director with Bertram, told PEO.
Bertram’s first fund closed on $350 million in August of 2006, and is currently roughly 80 percent invested. Through the end of 2009, the fund had an IRR of 18.4 percent.
Bertram’s investments are managed by Drazan, a founding partner of Menlo Park, California-based technology investor Sierra Ventures, and brother Ken Drazan, founder and former chief executive officer of biopharmaceutical company Arginox Pharmaceuticals.